AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04902287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Intervention for the Engagement of Families (TIES)
Description: This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
Study NCT06418542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: use of florescein
Description: Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
Study NCT04628507 — intervention group
Intervention type: OTHER
Intervention: Spent media collection
Description: Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
Study NCT06653621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
Study NCT06653621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block mode : adductor block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
Study NCT06653621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block mode : adductor block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
Study NCT06653621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
Study NCT06653621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block mode: femoral triangle block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
Study NCT06653621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block mode: femoral triangle block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
Study NCT04644718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
Study NCT04644718 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
Study NCT06170645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APA program
Description: An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
Study NCT06170645 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: APA program
Description: An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
Study NCT06170645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous VNS
Description: After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
Study NCT06170645 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous VNS
Description: After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
Study NCT06011486 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lymphocyte infusion (ImmuneCellVir-I)
Description: Infusion of donor CMV specific cells into patients eligible to the trial
Study NCT05559814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraluminal peppermint oil
Description: Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
Study NCT05559814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraluminal flushing of placebo solution through the scope during scope withdrawal
Study NCT04854655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resin composite
Description: nanofilled resin composite
Study NCT04854655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activa Presto
Description: calcium and phosphate hybrid material
Study NCT04854655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer
Description: fluoride releasing hybrid material
Study NCT06596304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity-resistance training with lower limb blood flow restriction
Description: In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
Study NCT06596304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Resistance Training
Description: In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
Study NCT06657079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
Description: combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
Study NCT06657079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline inhaler
Study NCT06656416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-100
Description: ALTO-100 40 mg tablet BID
Study NCT06656416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID
Study NCT06656559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab and Surufatinib
Description: Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
Study NCT06657417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Description: Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
Study NCT06657417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video larnygoscopy
Description: Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
Study NCT06656130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pranayama
Description: Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
Study NCT06656130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jacobson's progressive muscle relaxation technique
Description: Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
Study NCT06657664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy with sterile saline at 2.5ºC
Description: the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
Study NCT06657664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intaoral cryotherapy
Description: ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
Study NCT06657664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Both intracanal and intraoral cryotherapy
Description: Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
Study NCT06657664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
Study NCT06657664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: , all occlusal contacts were reduced by 1 mm
Study NCT05105633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
Study NCT05105633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (which may include intravenous Alteplase)
Description: Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
Study NCT05663788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning module
Description: The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes.
Study NCT05842707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dualCAR-NK19/70 cell
Description: Given by IV (vein)
Study NCT05125939 — intervention group
Intervention type: OTHER
Intervention: Comparison of ADR
Description: The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
Study NCT06657261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The patient group receiving deep and superficial serratus anterior plane block
Description: The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
Study NCT06657261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block
Description: The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
Study NCT04661813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXTRA-CVD Virtual Care
Description: The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination.
Study NCT06448988 — intervention group
Intervention type: OTHER
Intervention: Park Bench position
Description: To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
Study NCT04585763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)
Description: The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
Study NCT05415579 — intervention group
Intervention type: OTHER
Intervention: Traditional Chinese medicine (TCM)
Description: TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
Study NCT04665102 — intervention group
Intervention type: OTHER
Intervention: Image classification using deep learning algorithm
Description: Image classification using deep learning algorithm
Study NCT06487377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IX001 TCR-T cells
Description: IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
Study NCT04835753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave
Description: true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
Study NCT04835753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional physical therapy program
Description: lower limbs muscles stretch and strength in addition to balance and gait training
Study NCT04835753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: lower limbs muscles stretch and strength in addition to balance and gait training
Study NCT05721027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days
Study NCT05721027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days
Study NCT05721027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 16 mg PO during ED visit and next day
Study NCT05721027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
Study NCT05721027 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
Study NCT04795323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARA v3.1, only non-pharmacological self-management support
Description: Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
Study NCT04795323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARA v3.2, both non-pharmacological and pharmacological self-management support
Description: Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
Study NCT06439290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonosurgery
Description: Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
Study NCT01344200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Study NCT01344200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Study NCT06033664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
Study NCT04924790 — intervention group
Intervention type: BEHAVIORAL
Intervention: COVID-19 Pandemic
Description: Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
Study NCT06003179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses
Study NCT06003179 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo
Study NCT06003179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment
Study NCT06003179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment
Study NCT06367413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).